Call to Action: Chronic HBV Monitoring and Hepatocellular Carcinoma (HCC) Surveillance in Primary Care Settings
SmartMobile(TM)Premiere Date: Thursday, October 18, 2018
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, October 18, 2019
Note: Credit Is No Longer Available
|Joseph Ahn, MD, MS, FAASLD, FACG, AGAF
Professor of Medicine
Director of Clinical Hepatology
Oregon Health & Science University
The National Strategy for the Elimination of Hepatitis B and C Phase 2 Report was released in March 2017 and indicated that better attention to prevention, screening, and treatment of hepatitis B and C could eliminate the burden of these diseases and prevent nearly 90,000 deaths by 2030.
Regularly monitoring of disease status with HBV DNA is imperative to determine the need for antiviral therapy, and the guideline for HCC recommends surveillance of high risk persons every 6 months. Repeat lab testing is recommended as well, but this testing should not take the place of treatment consideration.
This CME Outfitters mobile case series is designed to help primary care and internal medicine clinicians improve their knowledge, confidence, and performance in employing monitoring strategies to assess treatment effectiveness in patients with HBV.
At the end of this CE activity, participants should be able to:
- Employ monitoring strategies to assess treatment effectiveness in patients with HBV, including evaluation of continued virological response and antiviral resistance. Identify evidence-based methods for the surveillance of the development of HCC in patients with chronic HBV.
Supported by an educational grant from Gilead Sciences, Inc.
Primary care physicians, internists, gastroenterologists, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with HBV.
CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse Practitioners can also apply for credit through their state boards.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Ahn reports that he is on the advisory board for Gilead.
Kashemi Rorie, PhD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Shari Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).